Twist Bioscience Corp
For the period ended Jun 30, 2024. Filed Aug 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 2, 2024
TWST$132.13-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of March 31, 2024 | 58,162 | $— | $1,682,473 | $(660) | $(1,121,682) | $560,131 | |||
| Vesting of restricted stock units | 223 | $— | $— | $— | $— | $— | |||
| Exercise of stock options | 134 | — | 2,915 | — | — | 2,915 | |||
| Repurchases of common stock for income tax withholding | — | — | (7) | — | — | (7) | |||
| Stock-based compensation | — | — | 13,746 | — | — | 13,746 | |||
| Other comprehensive income | — | — | — | (75) | — | (75) | |||
| Net loss | — | — | — | — | (85,571) | (85,571) | |||
| Balances as of June 30, 2024 | 58,519 | $— | $1,699,127 | $(735) | $(1,207,253) | $491,139 | |||
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveincome · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of March 31, 2023 | 57,105 | $— | $1,633,217 | $111 | $(929,396) | $703,932 | |||
| Vesting of restricted stock units | 182 | $— | $— | $— | $— | $— | |||
| Exercise of stock options | 45 | — | 342 | — | — | 342 | |||
| Repurchases of common stock for income tax withholding | (70) | — | (1,014) | — | — | (1,014) | |||
| Issuance of shares from business acquisition | 105 | — | 1,767 | — | — | 1,767 | |||
| Stock-based compensation | — | — | 10,664 | — | — | 10,664 | |||
| Other comprehensive income | — | — | — | (746) | — | (746) | |||
| Net loss | — | — | — | — | (57,395) | (57,395) | |||
| Balances as of June 30, 2023 | 57,367 | $— | $1,644,976 | $(635) | $(986,791) | $657,550 | |||
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveloss · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of September 30, 2023 | 57,557 | $— | $1,657,222 | $(756) | $(1,033,034) | $623,432 | |||
| Impact of ASU 2016-13 adoption (Note 2) | — | $— | $— | $— | $(148) | $(148) | |||
| Vesting of restricted stock units | 712 | — | — | — | — | — | |||
| Exercise of stock options | 261 | — | 5,183 | — | — | 5,183 | |||
| Issuance of shares under the employee stock purchase program | 124 | — | 2,047 | — | — | 2,047 | |||
| Repurchases of common stock for income tax withholding | (135) | — | (3,967) | — | — | (3,967) | |||
| Stock-based compensation | — | — | 38,642 | — | — | 38,642 | |||
| Other comprehensive income | — | — | — | 21 | — | 21 | |||
| Net loss | — | — | — | — | (174,071) | (174,071) | |||
| Balances as of June 30, 2024 | 58,519 | $— | $1,699,127 | $(735) | $(1,207,253) | $491,139 | |||
| Commonstock · Additional paid-incapital · Accumulated Othercomprehensiveincome · Accumulateddeficit · Totalstockholders'equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (In thousands) · Shares · Amount | |||||||||
| Balances as of September 30, 2022 | 56,523 | $— | $1,619,644 | $(1,843) | $(828,416) | $789,385 | |||
| Vesting of restricted stock units | 504 | $— | $— | $— | $— | $— | |||
| Exercise of stock options | 102 | — | 1,195 | — | — | 1,195 | |||
| Issuance of shares under the employee stock purchase plan | 132 | — | 2,536 | — | — | 2,536 | |||
| Repurchases of common stock for income tax withholding | (171) | — | (3,275) | — | — | (3,275) | |||
| Issuance of shares from business acquisition | 277 | — | 5,860 | — | — | 5,860 | |||
| Stock-based compensation | — | — | 19,016 | — | — | 19,016 | |||
| Other comprehensive income | — | — | — | 1,208 | — | 1,208 | |||
| Net loss | — | — | — | — | (158,375) | (158,375) | |||
| Balances as of June 30, 2023 | 57,367 | $— | $1,644,976 | $(635) | $(986,791) | $657,550 | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.